Department of Anaesthesiology and Intensive Care Medicine, Aarhus University Hospital, Aarhus Sygehus, Denmark.
Thromb Res. 2013 May;131(5):e210-3. doi: 10.1016/j.thromres.2013.02.009. Epub 2013 Mar 6.
Fibrinogen deficiency often develops during massive bleeding due to e.g. fluid resuscitation with colloid plasma expanders like hydroxyethyl starch. This study investigates the haemostatic effect of various sources of fibrinogen: fibrinogen concentrates (Haemocomplettan® (FC 1), CSL Behring and Clottagen® (FC 2), LFB Biomedicaments), fresh frozen plasma (FFP), and Cryoprecipitate (CP).
Whole blood samples provided by healthy individuals (n=8) were diluted 1:1 with HES or 0.9% isotonic saline as control. Various sources of fibrinogen was added to the HES diluted samples in concentrations equivalent to giving a 70 kg male either no correction, 2 grams of FC 1 or FC 2, 4 grams of FC 1 or FC 2, 15 ml/kg of FFP, 2 packs of CP or 4 packs of CP. Haemostatic effect was assessed by thromboelastometry initiated by tissue factor, with maximum clot firmness (MCF) as the primary endpoint. In addition thrombin generation was assessed for each intervention
HES dilution reduced MCF significantly more than isotonic saline. High dose FC 1, 2 and CP corrected the MCF so that it did not differ significantly from the isotonic saline dilution group. Thrombin generation following isotonic saline and HES dilution was comparable and not decreased compared to whole blood. Fibrinogen concentrates supplementation did not increase thrombin generation whereas CP and FFP both increased thrombin generation
Fibrinogen concentrates investigated dose dependently and equally corrected the MCF and caused no increase in thrombin generation. Cryoprecipitate also corrected the MCF, but also increased thrombin generation. FFP failed to improve MCF, but increased thrombin generation.
纤维蛋白原缺乏症常因胶体血浆扩容剂(如羟乙基淀粉)的液体复苏而在大量出血期间发生。本研究调查了各种纤维蛋白原来源的止血效果:纤维蛋白原浓缩物(Haemocomplettan®(FC 1),CSL Behring 和 Clottagen®(FC 2),LFB Biomedicaments)、新鲜冷冻血浆(FFP)和冷沉淀(CP)。
健康个体提供的全血样本(n=8)用 HES 或 0.9%等渗盐水(作为对照)按 1:1 稀释。将各种纤维蛋白原来源添加到 HES 稀释的样本中,浓度相当于给予 70 公斤男性无矫正、2 克 FC 1 或 FC 2、4 克 FC 1 或 FC 2、15 毫升/公斤 FFP、2 袋 CP 或 4 袋 CP。通过组织因子启动血栓弹性描记法评估止血效果,以最大凝块硬度(MCF)作为主要终点。此外,还评估了每种干预措施的凝血酶生成。
HES 稀释使 MCF 显著降低,明显多于等渗盐水。高剂量 FC 1、2 和 CP 纠正 MCF,使其与等渗盐水稀释组无显著差异。与全血相比,等渗盐水和 HES 稀释后凝血酶生成无差异且未减少。纤维蛋白原浓缩物补充未增加凝血酶生成,而 CP 和 FFP 均增加凝血酶生成。
研究中的纤维蛋白原浓缩物剂量依赖性和等效地纠正 MCF,且不会引起凝血酶生成增加。冷沉淀也纠正 MCF,但也增加凝血酶生成。FFP 未能改善 MCF,但增加凝血酶生成。